Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCanopy Growth Corp

Canopy Growth Corp

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.6515 USD -0.02 ( 3.58%)
Last update at 2026-11-06T21:16:00Z
VOLUME
6802935
Market Cap
511.95M

Momentum Score

…

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.58
Low
0.68
High
52 Week Price Range
0.84
Low
2.38
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Canopy Growth Corp is a Canadian cannabis company that cultivates, manufactures and sells cannabis and hemp-derived products for medical and consumer markets in Canada and select international markets. Long-term growth drivers include ongoing legalization and retail expansion, product diversification and scale from production and distribution, which may make the company attractive to investors seeking exposure to the legalized cannabis sector.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.68
Dividend Yield
-
Revenue TTM
278.39M
Revenue Per Share
1.16
Gross Profit TTM
73.94M
Debt / Equity
0.72
ROE
-48.50%
Net Debt
234.59M
ROCE
-63.46%
Diluted EPS TTM
-1.35

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Income before tax -597.00M -471.36M -3314.32M -329.43M -1683.96M
Minority interest 0.00M 18.53M 31.39M 18.30M 140.01M
Net income -598.12M -657.27M -3309.55M -320.49M -1670.82M
Selling general administrative 60.85M 104.44M 487.41M 520.28M 666.54M
Selling and marketing expenses 60.85M 76.14M 243.45M 239.28M 194.40M
Gross profit 79.51M 80.88M -104.14M -193.05M 66.96M
Reconciled depreciation 43.12M 53.18M 84.52M 114.42M 127.12M
Ebit -522.43M -366.00M 1665.19M -1082.67M 44.30M
Ebitda -479.31M -312.83M 1749.71M -229.58M 171.42M
Depreciation and amortization 43.12M 53.18M 84.52M 853.10M 127.12M
Operating income -117.14M -228.71M 1665.19M -1082.67M 44.30M
Other operating expenses 386.14M 525.86M 994.46M 1233.66M 1146.23M
Interest expense 74.57M 105.35M 126.16M 103.94M 8.46M
Tax provision 7.14M 12.33M -4.77M -8.95M -13.14M
Interest income 8.81M 16.23M 24.28M 6.60M 21.37M
Net interest income -65.75M -89.12M -101.88M -97.34M 12.91M
Income tax expense 7.14M 12.33M -4.77M -8.95M -13.14M
Total revenue 269.00M 297.15M 402.90M 520.33M 546.65M
Total operating expenses 196.65M 309.60M 487.41M 520.28M 666.54M
Cost of revenue 189.48M 216.26M 507.04M 713.38M 479.69M
Total other income expense net -479.85M -242.64M -4979.51M 753.24M -1728.26M
Net income from continuing ops -604.14M -483.68M -3309.55M -320.49M -1670.82M
Net income applicable to common shares - - - -302.18M -1744.92M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Total assets 917.70M 1300.33M 2439.10M 5615.05M 6823.48M
Intangible assets 87.20M 104.05M 188.72M 252.69M 308.17M
Other current assets 13.95M 45.48M 10.12M 19.07M 67.23M
Total liab 430.49M 799.82M 1679.08M 1984.55M 3201.66M
Total stockholder equity 487.21M 500.37M 758.43M 3589.96M 3481.81M
Other current liab 34.43M 70.57M 94.73M 139.33M 106.43M
Common stock 8796.41M 8244.30M 7938.57M 7482.81M 7168.56M
Capital stock 8796.41M 8244.30M 7938.57M 7482.81M 7168.56M
Retained earnings -10928.15M -10330.03M -9672.76M -6370.34M -6068.16M
Other liab - - - 89.91M 1250.03M
Good will 46.04M 43.24M 85.56M 1866.50M 1889.35M
Other assets - 0.00M - 15.34M 4.96M
Cash 113.81M 170.30M 677.01M 776.00M 1154.65M
Total current liabilities 94.40M 234.72M 803.84M 212.90M 284.33M
Current deferred revenue - 5.85M 75.99M - 100.81M
Net debt 234.59M 497.70M 629.87M 724.99M 428.31M
Short term debt 20.80M 119.11M 556.89M 9.30M 9.83M
Short long term debt 4.26M 103.94M 556.89M 9.30M 9.83M
Short long term debt total 348.40M 668.00M 1306.88M 1500.99M 1582.96M
Other stockholder equity 2618.42M 2602.15M -7166.28M 2519.77M 2415.65M
Property plant equipment - - - 942.78M 1074.54M
Total current assets 294.57M 371.18M 1077.25M 1737.40M 2838.19M
Long term investments 35.29M 136.22M 568.29M 341.73M 708.27M
Net tangible assets - - - 1470.76M 1284.29M
Short term investments 17.66M 33.16M 105.59M 595.65M 1144.56M
Net receivables 52.78M 44.94M 93.99M 96.44M 92.44M
Long term debt 299.81M 493.29M 749.99M 1491.69M 1573.14M
Inventory 96.37M 77.29M 148.90M 204.39M 367.98M
Accounts payable 26.10M 28.67M 76.23M 64.27M 67.26M
Accumulated other comprehensive income 0.54M -16.05M -13.86M -42.28M -34.24M
Common stock total equity - - - - 7168.56M
Non currrent assets other 161.07M 325.53M 19.45M -0.65M -16.42M
Non current assets total 623.13M 929.15M 1361.84M 3877.65M 3985.29M
Capital lease obligations 44.33M 70.77M 109.31M 139.16M 136.22M
Breakdown 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Type yearly yearly yearly yearly yearly
Date 2025-03-31 2024-03-31 2023-03-31 2022-03-31 2021-03-31
Investments -47.79M 241.59M 433.38M 166.58M -497.56M
Change to liabilities - - - -35.84M -9.63M
Total cashflows from investing activities -47.79M 241.59M - 230.82M -884.11M
Net borrowings -220.78M -509.78M - -50.76M 877.54M
Total cash from financing activities 148.66M -465.06M -19.69M -45.53M 1264.77M
Change to operating activities - - - 24.47M 0.08M
Net income -604.14M -483.68M -3309.55M -320.49M -1670.82M
Change in cash -56.49M -506.71M -99.00M -378.65M -148.52M
Begin period cash flow 170.30M 677.01M 776.00M 1154.65M 1303.18M
End period cash flow 113.81M 170.30M 677.01M 776.00M 1154.65M
Total cash from operating activities -165.75M -281.95M -557.55M -545.81M -465.73M
Issuance of capital stock 385.39M 81.06M 1.05M 2.70M 1.38M
Depreciation 43.12M 53.18M 84.52M 114.42M 127.12M
Other cashflows from investing activities 48.90M 167.79M - -18.13M -66.75M
Change to inventory -17.71M 1.03M 55.64M 173.19M 17.21M
Change to account receivables -4.49M -3.75M - 3.74M 9.63M
Other cashflows from financing activities -15.96M -36.34M 97.44M 2.53M 1279.01M
Change to netincome - - - -523.61M 1156.41M
Capital expenditures 11.28M 4.00M 10.55M 48.11M 174.14M
Change in working capital -31.96M 3.97M 65.84M 165.56M -4.33M
Stock based compensation -4.21M 14.18M 31.19M 47.52M 91.15M
Other non cash items 424.30M 118.08M 2575.22M -543.88M 1004.30M
Free cash flow -177.03M -285.95M -568.10M -593.92M -639.87M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CGC
Canopy Growth Corp		 -0.02
3.58%		 0.65 - 20.37 1.84 0.93 2.09 11014.10
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Canopy Growth Corp

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis, hemp, and cannabis-related products in Canada, Germany, and Australia. It operates through four segments: Canada Cannabis, International Markets Cannabis, and Storz & Bickel, and This Works. The company offers dried flower and pre-rolled joints; extracts and concentrates, such as softgel capsules; cannabis edibles, including gummies; cannabis vapes; and oils, beverages, concentrates. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Wana, and Claybourne brands, as well as DOJA, LivRelief, Ace Valley, and Vert brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.

1 Hershey Drive, Smiths Falls, ON, Canada, K7A 0A8

855 558 9333

https://www.canopygrowth.com

960

Name Title Year Born
Mr. David Eric Klein CEO & Director 1964
Ms. Judy Eunjoo Hong VP of Investor Relations & Competitive Intelligence, Chief of Staff to the CEO and CFO 1973
Mr. Julious C. Grant Jr. Chief Commercial Officer 1968
Mr. Jonathan Di Tosto Chief Operations Officer NA
Mr. Thomas Carlton Stewart VP & Chief Accounting Officer 1982
Mr. Thomas Shipley IV Sr. VP of Quality Assurance & Chief Science Officer 1989
Dr. Christelle Gedeon L.L.B., Ph.D. Chief Legal Officer 1982
Mr. Timothy Rob Saunders F.C.A., FCPA Strategic Advisor 1961
Jason Green Head of Agriculture - Hemp Division NA
Dr. Mark A. Ware Chief Medical Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…